Showing results 32 to 34 of 34
< previous
| Issue Date | Title | Author(s) |
| 1-Nov-2014 | Use of maraviroc in patients with undetectable viral load: efficacy,
tolerance and predictors of viral response in MARAVIROC-cohort
study | Pérez Elías, María Jesús; Arroyo, David; Diaz, Alberto; Herrero, Cristina; Martinez Dueñas, Loreto; Moreno, Ana; Hernández Quero, José; Podzamczer Palter, Daniel; Gómez Ayerbe, Cristina; Casado, José Luis; Zamora, Javier; Rivero, Antonio; Moreno Guillén, Santiago; Llibre, Josep María |
| 1-Oct-2019 | Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1 | Podzamczer Palter, Daniel; EMERALD study group |
| 1-Apr-2020 | Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients | Orkin, Chloe; Eron, Joseph J.; Rockstroh, Jürgen Kurt; Podzamczer Palter, Daniel; Esser, Stefan; Vandekerckhove, Linos; Van Landuyt, Erika; Lathouwers, Erkki; Hufkens, Veerle; Jezorwski, John; Opsomer, Magda; AMBER study group |
